CRDF (Cardiff Oncology, Inc.) Stock Financials & Earnings | Market Cap Arena

CRDF (Cardiff Oncology, Inc.) Stock Financials & Earnings | Market Cap Arena

CRDFCardiff Oncology, Inc.

Mkt Cap$139M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Revenue (TTM)$593,000

Net Income (TTM)-$46M

EPS (TTM)-$0.77

Free Cash Flow (TTM)-$38M

Gross Margin-1890.4%

Op. Margin-8256.3%

Net Margin-7732.2%

FCF Margin-6402.5%

P/S Ratio (TTM)234.6x

P/E Ratio (TTM)—

YoY Rev Growth-13.3%

Employees—

Earnings Reports

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q1 23	$83K	$83K	-$12M
Q2 23	$108K	$108K	-$12M
Q3 23	$141K	$34K	-$11M
Q4 23	$156K	$53K	-$10M
Q1 24	$205K	$103K	-$11M
Q2 24	$163K	$58K	-$13M
Q3 24	$165K	-$9M	-$13M
Q4 24	$151K	$151K	-$13M
Q1 25	$109K	$109K	-$14M
Q2 25	$121K	-$11M	-$15M
Q3 25	$120K	$120K	-$12M
Q4 25	$243K	$20K	-$8M

Valuation

Quarter	P/S	P/E
Q1 23	352.2x	—
Q2 23	337.7x	—
Q3 23	302.4x	—
Q4 23	285.1x	—
Q1 24	228.1x	—
Q2 24	209.2x	—
Q3 24	201.9x	—
Q4 24	203.4x	—
Q1 25	236.6x	—
Q2 25	254.8x	—
Q3 25	277.7x	—
Q4 25	234.6x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 23	-$9M	-$9M
Q2 23	-$7M	-$7M
Q3 23	-$8M	-$8M
Q4 23	-$7M	-$7M
Q1 24	-$8M	-$8M
Q2 24	-$9M	-$9M
Q3 24	-$10M	-$10M
Q4 24	-$10M	-$10M
Q1 25	-$13M	-$13M
Q2 25	-$8M	-$8M
Q3 25	-$11M	-$11M
Q4 25	-$6M	-$6M

Capital Expenditures

CapEx

Quarter	CapEx
Q1 23	$8K
Q2 23	$251K
Q3 23	$315K
Q4 23	$8K
Q1 24	$80K
Q2 24	$0
Q3 24	$0
Q4 24	$0
Q1 25	$0
Q2 25	$26K
Q3 25	$18K
Q4 25	$0

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 23	+12.2%	+8.9%
Q2 23	+18.7%	+16.9%
Q3 23	+51.6%	+20.6%
Q4 23	+21.9%	+10.2%
Q1 24	+147.0%	-8.2%
Q2 24	+50.9%	+3.2%
Q3 24	+17.0%	+16.5%
Q4 24	-3.2%	+21.3%
Q1 25	-46.8%	+30.1%
Q2 25	-25.8%	+17.2%
Q3 25	-27.3%	-5.3%
Q4 25	+60.9%	-36.6%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 23	$1M	1281.9%
Q2 23	$2M	1463.9%
Q3 23	$955K	677.3%
Q4 23	$909K	582.7%
Q1 24	$1M	548.3%
Q2 24	$1M	723.3%
Q3 24	$1M	759.4%
Q4 24	$1M	797.4%
Q1 25	$1M	1252.3%
Q2 25	$2M	1390.9%
Q3 25	$1M	1153.3%
Q4 25	$1M	518.9%

OpEx Breakdown

Quarter	R&D	G&A	S&M
Q1 23	$9M	$3M	—
Q2 23	$8M	$4M	$584K
Q3 23	$8M	$2M	$536K
Q4 23	$8M	$4M	—
Q1 24	$8M	$3M	—
Q2 24	$9M	$3M	$459K
Q3 24	$10M	—	—
Q4 24	$10M	$3M	—
Q1 25	$10M	$4M	—
Q2 25	$12M	—	—
Q3 25	$8M	$4M	—
Q4 25	$5M	$4M	—

Revenue Segments

Quarter

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 23	$15M	$82M	$97M
Q2 23	$19M	$70M	$89M
Q3 23	$15M	$66M	$81M
Q4 23	$22M	$53M	$75M
Q1 24	$19M	$49M	$67M
Q2 24	$26M	$35M	$60M
Q3 24	$13M	$45M	$58M
Q4 24	$51M	$40M	$92M
Q1 25	$24M	$56M	$80M
Q2 25	$11M	$60M	$71M
Q3 25	$10M	$50M	$61M
Q4 25	$17M	$41M	$58M

Shares Outstanding

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change
Q1 23	45M	+0.0%
Q2 23	45M	+0.0%
Q3 23	45M	+0.0%
Q4 23	45M	+0.0%
Q1 24	45M	+0.0%
Q2 24	45M	+0.3%
Q3 24	47M	+4.6%
Q4 24	48M	+1.7%
Q1 25	48M	+0.0%
Q2 25	67M	+39.6%
Q3 25	67M	+0.5%
Q4 25	67M	-0.1%

Revenue Per Employee

Revenue / Employee

Year	Revenue/Employee	Employees
FY 14	$56K	5
FY 15	$4K	72
FY 16	$7K	53
FY 17	$30K	17
FY 18	$29K	13
FY 19	$17K	14
FY 20	$31K	12
FY 21	$16K	23
FY 22	$15K	26
FY 23	$15K	32
FY 24	$21K	33
FY 25	$19K	31